AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin injection
Description: administered via IV infusion
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: administered via IV infusion
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel injection
Description: administered via IV infusion
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: administered via IV infusion
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed Disodium
Description: administered via IV infusion
Study NCT03711084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural high potency sweetener from leaf extract
Description: Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full.
Study NCT03711084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full.
Study NCT03711084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full.
Study NCT03711084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full.
Study NCT03711084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full.
Study NCT03611075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No interventions are administered in this study
Study NCT04185961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVERA-RAPHA with 60mmHG
Description: Apply EVERA-RAPHA with 60mmHG for 4weeks
Study NCT04185961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVERA-RAPHA with 100mmHG
Description: Apply EVERA-RAPHA with 100mmHG for 4weeks
Study NCT01232959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal Cholecystectomy
Description: A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
Study NCT01839318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A contact lenses
Study NCT01839318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lenses
Study NCT01333800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beclomethasone
Description: 200 to 400 mcg per day for 6 months
Study NCT01333800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 80 to 160 mcg per day for 6 months
Study NCT03137836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM .
Study NCT01237496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly
Study NCT03643055 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-fluorocholine PET/CT
Description: 18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
Study NCT01079949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hLH + r-hFSH
Description: Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
Study NCT01079949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-hFSH
Description: Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
Study NCT01079949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
Study NCT01079949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
Study NCT01079949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (>=) 14 mm, and maintained until at least one follicle of >=18 mm and two additional follicles of >=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
Study NCT01079949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (>=) 14 mm, and maintained until at least one follicle of >=18 mm and two additional follicles of >=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
Study NCT00780910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: 750 mg every 8 hours for 12 weeks
Study NCT00780910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 24 weeks
Study NCT00780910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 24 weeks
Study NCT04105127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic - Anterior resin builds-ups
Description: After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
Study NCT04105127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic - Posterior resin builds-ups
Description: After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
Study NCT00368979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: once daily
Study NCT00368979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT00089024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 \& 2; Repeat one 3-week cycle starting day 22
Study NCT00089024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 \& 2; Repeat one 3-week cycle starting day 22
Study NCT00089024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
Study NCT00089024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: administered via IV infusion
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo to match tislelizumab IV infusion
Study NCT01859884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inform Me: web-based education tool
Description: The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
Study NCT04379869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: Single dose of NNZ-2591
Study NCT04379869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Comparator for double-blind MAD
Study NCT02448524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent
Description: Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
Study NCT02733887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
Study NCT02733887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: 18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
Study NCT02448524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIVOLI
Description: Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
Study NCT02733887 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
Study NCT06251674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: long-axis needle release
Description: The participants received one session of ultrasound-guided long-axis TCL needle release.
Study NCT06251674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: short-axis needle release
Description: The participants received one session of ultrasound-guided long-axis TCL needle release.
Study NCT00476463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
Study NCT03484949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre-endoscopic screening risk assessment
Description: pre-endoscopic screening risk assessment
Study NCT02355041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Replacement-based Weight Loss Diet
Study NCT02355041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Video
Description: Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
Study NCT00984152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
Description: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
Study NCT00984152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC + Efavirenz (Atripla) Once-Daily
Description: TDF/FTC + Efavirenz (Atripla) Once-Daily
Study NCT00930501 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood tests
Description: time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
Study NCT05346380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus VE2 NIR Imaging System
Description: A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.
Study NCT05346380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: administered via IV infusion
Study NCT02629887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-inflatable supraglottic airway
Description: at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
Study NCT02629887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face Mask
Description: at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
Study NCT02629887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-Piece Resuscitator
Description: T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
Study NCT00170846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Study NCT00170846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin Inhibitors (CNI)
Study NCT00170846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin Inhibitors (CNI)
Study NCT00170846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate acid (MPA)/Azathioprine (AZA)
Study NCT00170846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate acid (MPA)/Azathioprine (AZA)
Study NCT00170846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Study NCT04379635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: administered via IV infusion
Study NCT00170846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Study NCT00224120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: 8 mg daily for 12 weeks
Study NCT00224120 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for 12 weeks
Study NCT04808726 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teach Back Method
Description: Effect of Breastfeeding Training on Breastfeeding Success Using The Teach Back Method: Randomized Controlled Study
Study NCT04644146 — intervention group
Intervention type: GENETIC
Intervention: GENETIC
Description: It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
Study NCT00438360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A microemulsion
Description: Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
Study NCT00438360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
Study NCT03072394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic
Description: Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
Study NCT03072394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
Study NCT00967694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: Nitrous oxide sedation by inhalation
Study NCT02303756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillcam® COLON Capsule
Description: colonoscopy
Study NCT01334216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHICA Smoking Cessation Module
Description: The CHICA module helped to screen parents for smoking and assist them in quitting.
Study NCT01334216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CHICA Placebo
Description: This was CHICA without the study module.
Study NCT04333888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: fMRI neurofeedback training of amygdala downregulation
Study NCT00140907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: 25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.